ClinicalTrials.gg
CompletedNCT01461460Updated Dec 5, 2018

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

A Phase 1 interventional study of TR-701 FA 1200 mg and Moxifloxacin 400 mg in Healthy Volunteer, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-05.

Sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effects of oral TR-701 free acid (FA) versus placebo on QTcF.

Read the detailed description

To assess the effects of a single therapeutic (200 mg) and supratherapeutic of oral TR-701 free acid (FA) versus placebo on QT interval corrected for heart rate using Fridericia's formula (QTcF) in healthy subjects.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • volunteer
03

In context

Lead sponsor

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 19 studies on the registry; none are open to participants now.

First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 and 45 years of age, inclusive.
  • Healthy males and females with no abnormalities.
  • ≥18.0 kg/m2 and ≤30.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Sustained supine systolic blood pressure >140 or \<100 mmHg or a diastolic blood pressure >90 or \<60 mmHg at the Screening and Day 1 Visit.
  • Abnormal at Screening or Day -1 Visits indicating a second or third-degree atrioventricular block, or QRS >110 msec, >450 msec for males and >470 msec for females, PR interval >200 msec, or any rhythm other than sinus rhythm which is interpreted by the Investigator as - History of unexplained infections or current signs of infection
  • History of risk factors for Torsades de Pointes, including unexplained syncope, known Long QT Syndrome, heart failure, myocardial infarction, angina, or clinically significant abnormal laboratory assessments including hypokalemia, hypercalcemia, hypomagnesemia, or family history of Long QT Syndrome or Brugada Syndrome
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Moxifloxacin 400 mg

    Drug: Moxifloxacin 400 mg

  • Experimental
    TR-701 FA 1200 mg

    Drug: TR-701 FA 1200 mg

  • Experimental
    TR-701 FA 200 mg plus Placebo

    Drug: TR-701 FA 200 mg plus Placebo

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 6 tablet of T-701 FA

    Also known as: Tedizolid

  • 1 tablet 400 mg Moxifloxacin

  • DrugTR-701 FA 200 mg plus Placebo

    Drug page: Tedizolid

    1 tablet of TR-701 FA with 5 tablet placebo

    Also known as: Tedizolid

  • DrugPlacebo

    6 placebo tablets

06

What researchers measure

Primary outcomes

  1. QTcF Change from Baseline

    Time-matched, placebo adjusted change from the baseline QTcF (ΔΔQTcF).

    Time frame: 24 Hours

07

Study locations

1 site
  • Trius Investigator
    Dallas, Texas 75247, United States
08

References and documents

Publications

  • Flanagan S, Litwin J, Fang E, Prokocimer P. Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled study. Int J Antimicrob Agents. 2016 Jul;48(1):33-40. doi: 10.1016/j.ijantimicag.2015.12.015. Epub 2016 Jun 2. PubMed 27342387 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2011 to primary completion in Dec 2011, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2011
First posted
Oct 28, 2011
StartActual
Nov 28, 2011
Primary completionActual
Dec 23, 2011
CompletionActual
Dec 23, 2011
Last update
Dec 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01461460
Responsible party
Sponsor
First posted
Oct 28, 2011
Start date
Nov 28, 2011
Primary completion
Dec 23, 2011
Completion
Dec 23, 2011
Last update
Dec 5, 2018

Study contacts

Philippe G Prokocimer, MD
study chair · Trius Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tedizolid phosphate · Tedizolid

Start the discussion